Skip to content
FY'25FY'24FY'23FY'22
Returns
Return on equity-24.7%+42.9pp-67.6%-54.0pp-13.6%+7.8pp-21.4%+18.2pp
Return on assets-23.8%+41.5pp-65.3%-52.1pp-13.2%+7.1pp-20.3%+16.4pp
Return on invested capital-32.6%
Liquidity
Current ratio22.4×-6.5×28.9×-30.1×59×+21.3×37.7×+22.2×
Quick ratio22.4×-6.5×28.9×-30.1×59×+21.3×37.7×+22.2×
Cash ratio3.1×-1.7×4.7×-54.0×58.8×+21.3×37.5×+22.2×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Valuation
Market capitalization$1.47B+116%$678.62M
Enterprise value$1.42B+130%$618.01M
Price / book3.1×+1.3×1.8×
Free cash flow yield-6%
Earnings yield-7.2%+13.7pp-20.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Oruka Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.